| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.34 | 5e-13 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.3 | 6e-10 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.32 | 4e-07 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.29 | 2e-06 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.2 | 1e-05 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.001 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.16 | 0.001 |
| mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.005 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.18 | 0.005 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.16 | 0.008 |